image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 8.07
-0.738 %
$ 737 M
Market Cap
-5.72
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one MYGN stock under the worst case scenario is HIDDEN Compared to the current market price of 8.07 USD, Myriad Genetics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one MYGN stock under the base case scenario is HIDDEN Compared to the current market price of 8.07 USD, Myriad Genetics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one MYGN stock under the best case scenario is HIDDEN Compared to the current market price of 8.07 USD, Myriad Genetics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart MYGN

image
$26.0$26.0$24.0$24.0$22.0$22.0$20.0$20.0$18.0$18.0$16.0$16.0$14.0$14.0$12.0$12.0$10.0$10.0$8.0$8.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
753 M REVENUE
11.03%
-257 M OPERATING INCOME
-108.08%
-263 M NET INCOME
-135.09%
-111 M OPERATING CASH FLOW
-4.33%
31.9 M INVESTING CASH FLOW
141.16%
153 M FINANCING CASH FLOW
2011.25%
213 M REVENUE
0.85%
-20 M OPERATING INCOME
45.21%
-22.1 M NET INCOME
39.78%
700 K OPERATING CASH FLOW
-73.08%
7.5 M INVESTING CASH FLOW
217.19%
-3.1 M FINANCING CASH FLOW
-129.17%
Balance Sheet Myriad Genetics, Inc.
image
Current Assets 314 M
Cash & Short-Term Investments 141 M
Receivables 114 M
Other Current Assets 58.4 M
Non-Current Assets 833 M
Long-Term Investments 0
PP&E 181 M
Other Non-Current Assets 652 M
12.29 %9.97 %5.09 %15.75 %56.89 %Total Assets$1.1b
Current Liabilities 156 M
Accounts Payable 25.8 M
Short-Term Debt 16.2 M
Other Current Liabilities 114 M
Non-Current Liabilities 207 M
Long-Term Debt 136 M
Other Non-Current Liabilities 71.5 M
7.10 %4.46 %31.35 %37.41 %19.68 %Total Liabilities$363.3m
EFFICIENCY
Earnings Waterfall Myriad Genetics, Inc.
image
Revenue 753 M
Cost Of Revenue 236 M
Gross Profit 517 M
Operating Expenses 774 M
Operating Income -257 M
Other Expenses 5.9 M
Net Income -263 M
800m800m600m600m400m400m200m200m00(200m)(200m)(400m)(400m)753m(236m)517m(774m)(257m)(6m)(263m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
68.64% GROSS MARGIN
68.64%
-34.17% OPERATING MARGIN
-34.17%
-34.96% NET MARGIN
-34.96%
-33.62% ROE
-33.62%
-22.97% ROA
-22.97%
-25.67% ROIC
-25.67%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Myriad Genetics, Inc.
image
200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)201620162017201720182018201920192020202020212021202220222023202320242024
Net Income -263 M
Depreciation & Amortization 61.9 M
Capital Expenditures -73.3 M
Stock-Based Compensation 40.7 M
Change in Working Capital 27 M
Others 52.1 M
Free Cash Flow -184 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Myriad Genetics, Inc.
image
Wall Street analysts predict an average 1-year price target for MYGN of $25.8 , with forecasts ranging from a low of $11.5 to a high of $35 .
MYGN Lowest Price Target Wall Street Target
11.5 USD 42.50%
MYGN Average Price Target Wall Street Target
25.8 USD 219.43%
MYGN Highest Price Target Wall Street Target
35 USD 333.71%
Price
Max Price Target
Min Price Target
Average Price Target
35353030252520201515101055May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Myriad Genetics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
2.89 M USD 6
9-12 MONTHS
6.05 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Is Myriad Genetics Stock Worth Holding in Your Portfolio Now? Strategic progress and solid potential in oncology testing keep MYGN on investors' radar. zacks.com - 3 weeks ago
Medical Equipment Stock Jumps on Upgrade Medical equipment stock Myriad Genetics Inc (NASDAQ:MYGN) was last seen up 9.8% at $11.25, after an upgrade from Piper Sandler to "overweight" from "neutral," with a price-target hike to $12.50 from $11.50. schaeffersresearch.com - 1 month ago
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO On Monday, in its earnings release, Myriad Genetics Inc. MYGN said Unitedhealth Group Inc's UNH UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including Myriad Genetics' GeneSight test, for its commercial, individual exchange, and certain managed Medicaid plans. This change takes effect in the first half of 2025. benzinga.com - 1 month ago
MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down Myriad Genetics achieves strong revenue growth in the fourth quarter of 2024. zacks.com - 1 month ago
Myriad Genetics, Inc. (MYGN) Q4 2024 Earnings Call Transcript Myriad Genetics, Inc. (NASDAQ:MYGN ) Q4 2024 Results Conference Call February 24, 2025 4:30 PM ET Company Participants Matt Scalo - Senior Vice President of Investor Relations Paul Diaz - President and Chief Executive Officer Sam Raha - Chief Operating Officer Mark Verratti - Chief Commercial Officer Scott Leffler - Chief Financial Officer Conference Call Participants Madeline Mollman - Wolfe Research Will Ortmayer - Goldman Sachs Madison Pasterchick - Morgan Stanley Tycho Peterson - Jefferies Sung Ji Nam - Scotia Bank Bill Bonello - Craig-Hallum Puneet Souda - Leerink Partners Ben Mee - Stephens Operator Good day, and thank you for standing by. Welcome to the Myriad Genetics Fourth Quarter 2024 Financial Earnings Conference Call. seekingalpha.com - 1 month ago
Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 month ago
Myriad Genetics (MYGN) Meets Q4 Earnings Estimates Myriad Genetics (MYGN) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.04 per share a year ago. zacks.com - 1 month ago
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth Highlights Fourth quarter 2024 revenue of $211 million, grew 7% year-over-year driven by continued demand for Pharmacogenomics (14%) and Prenatal (12%) testing. Fourth quarter GAAP gross margin of 71.7%, increased 300 basis points year-over-year, benefiting from improving revenue per test trends and greater laboratory efficiencies. globenewswire.com - 1 month ago
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial intelligence (AI)-enabled prognostic and predictive tests for advancing access to personalized medicine and empowering treatment decisions, announced that they have entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQ's AI technology platform for prostate cancer, in the United States. Machine learning and AI-enabled diagnostics are transforming the way clinicians approach cancer patient care. globenewswire.com - 1 month ago
Myriad Genetics Included in Forbes America's Best Employers 2025 List SALT LAKE CITY, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, has been named on the Forbes list of America's Best Employers 2025. globenewswire.com - 2 months ago
MYGN Stock Might Rise on Collaboration With CancerCARE Myriad Genetics entered into an agreement with CancerCARE for Life to provide individuals within the latter's network with access to the MyRisk Hereditary Cancer Test. zacks.com - 2 months ago
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced an agreement designed to enhance education and access to hereditary cancer testing for CancerCARE for Life members. The agreement enables more than one million individuals within CancerCARE's network to assess their eligibility for the MyRisk test by taking the MyGeneHistory ® quiz, a guideline-based online patient screening tool. globenewswire.com - 2 months ago
8. Profile Summary

Myriad Genetics, Inc. MYGN

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 737 M
Dividend Yield 0.00%
Description Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Contact 320 Wakara Way, Salt Lake City, UT, 84108 https://myriad.com
IPO Date Oct. 6, 1995
Employees 2700
Officers Mr. Samraat S. Raha Chief Operating Officer Ms. Jennifer L. Fox Chief Legal Officer Mr. Glenn Farrell Senior Vice President & Chief Marketing Officer Mr. Matthew Scalo Senior Vice President of Investor Relations Mr. Scott J. Leffler Chief Financial Officer Ms. Natalie Munk Senior Vice President & Chief Accounting Officer Mr. Paul J. Diaz J.D. Chief Executive Officer, President & Director Dr. Dale Muzzey Ph.D. Chief Scientific Officer Mr. Mark S. Verratti Chief Commercial Officer Dr. Kevin Richard Haas Ph.D. Chief Technology Officer